RU2014124984A - Конъюгаты антитело-лекарственное средство и родственные соединения, композиции и способы - Google Patents
Конъюгаты антитело-лекарственное средство и родственные соединения, композиции и способы Download PDFInfo
- Publication number
- RU2014124984A RU2014124984A RU2014124984A RU2014124984A RU2014124984A RU 2014124984 A RU2014124984 A RU 2014124984A RU 2014124984 A RU2014124984 A RU 2014124984A RU 2014124984 A RU2014124984 A RU 2014124984A RU 2014124984 A RU2014124984 A RU 2014124984A
- Authority
- RU
- Russia
- Prior art keywords
- linker
- antibody
- paragraphs
- conjugate
- formula
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 3
- 229940126601 medicinal product Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000000611 antibody drug conjugate Substances 0.000 claims abstract 18
- 229940049595 antibody-drug conjugate Drugs 0.000 claims abstract 18
- 239000002619 cytotoxin Substances 0.000 claims abstract 13
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 claims abstract 6
- 229930195731 calicheamicin Natural products 0.000 claims abstract 6
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 claims abstract 5
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims abstract 4
- 206010028980 Neoplasm Diseases 0.000 claims abstract 4
- 201000011510 cancer Diseases 0.000 claims abstract 4
- 229960000575 trastuzumab Drugs 0.000 claims abstract 4
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 claims abstract 3
- 101710112752 Cytotoxin Proteins 0.000 claims abstract 3
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical group CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 claims abstract 3
- 108010044540 auristatin Proteins 0.000 claims abstract 3
- 231100000599 cytotoxic agent Toxicity 0.000 claims abstract 3
- 108010093470 monomethyl auristatin E Proteins 0.000 claims abstract 3
- 108010059074 monomethylauristatin F Proteins 0.000 claims abstract 3
- 229960000548 alemtuzumab Drugs 0.000 claims abstract 2
- 239000000427 antigen Substances 0.000 claims abstract 2
- 102000036639 antigens Human genes 0.000 claims abstract 2
- 108091007433 antigens Proteins 0.000 claims abstract 2
- 125000004429 atom Chemical group 0.000 claims abstract 2
- 229960000397 bevacizumab Drugs 0.000 claims abstract 2
- 229960000455 brentuximab vedotin Drugs 0.000 claims abstract 2
- 229960005395 cetuximab Drugs 0.000 claims abstract 2
- 229960000578 gemtuzumab Drugs 0.000 claims abstract 2
- 229960002450 ofatumumab Drugs 0.000 claims abstract 2
- 229960001972 panitumumab Drugs 0.000 claims abstract 2
- 229960004641 rituximab Drugs 0.000 claims abstract 2
- 125000004434 sulfur atom Chemical group 0.000 claims abstract 2
- 229960005267 tositumomab Drugs 0.000 claims abstract 2
- 239000000562 conjugate Substances 0.000 claims 17
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 11
- 125000000217 alkyl group Chemical group 0.000 claims 9
- 229910052736 halogen Inorganic materials 0.000 claims 9
- 150000002367 halogens Chemical group 0.000 claims 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 9
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 7
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 5
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 4
- 229940125644 antibody drug Drugs 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 3
- 229910052794 bromium Inorganic materials 0.000 claims 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 239000000460 chlorine Substances 0.000 claims 2
- 125000001624 naphthyl group Chemical group 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- -1 trifluoromethanesulfonyloxy, benzenesulfonyloxy Chemical group 0.000 claims 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- 239000011630 iodine Substances 0.000 claims 1
- 229960005386 ipilimumab Drugs 0.000 claims 1
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 abstract 1
- WHGCQQXCXRCXJW-UZNIZVIGSA-N CC[C@H](C)[C@@H](C(N(C)[C@H](C[C@H](c1nc(C(N[C@H](C[C@H](C)C(O)=O)Cc2ccccc2)=O)c[s]1)OC(C)=O)C(C)C)=O)NC([C@@H]1NCCCC1)=O Chemical compound CC[C@H](C)[C@@H](C(N(C)[C@H](C[C@H](c1nc(C(N[C@H](C[C@H](C)C(O)=O)Cc2ccccc2)=O)c[s]1)OC(C)=O)C(C)C)=O)NC([C@@H]1NCCCC1)=O WHGCQQXCXRCXJW-UZNIZVIGSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161566909P | 2011-12-05 | 2011-12-05 | |
| US61/566,909 | 2011-12-05 | ||
| PCT/US2012/067803 WO2013085925A1 (en) | 2011-12-05 | 2012-12-04 | Antibody-drug conjugates and related compounds, compositions, and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2014124984A true RU2014124984A (ru) | 2016-01-27 |
Family
ID=48574809
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014124984A RU2014124984A (ru) | 2011-12-05 | 2012-12-04 | Конъюгаты антитело-лекарственное средство и родственные соединения, композиции и способы |
Country Status (17)
Families Citing this family (128)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101098854B (zh) | 2004-07-23 | 2012-12-05 | 恩多塞特公司 | 二价连接体及其轭合物 |
| EP2139523B1 (en) | 2007-03-14 | 2014-10-22 | Endocyte, Inc. | Conjugates of folate and tubulysin for targeted drug delivery |
| US9877965B2 (en) | 2007-06-25 | 2018-01-30 | Endocyte, Inc. | Vitamin receptor drug delivery conjugates for treating inflammation |
| AU2008268432B2 (en) | 2007-06-25 | 2015-01-15 | Endocyte, Inc. | Conjugates containing hydrophilic spacer linkers |
| WO2013121175A1 (en) | 2012-02-16 | 2013-08-22 | Ucl Business Plc | Lysosome-cleavable linker |
| WO2013126797A1 (en) | 2012-02-24 | 2013-08-29 | Purdue Research Foundation | Cholecystokinin b receptor targeting for imaging and therapy |
| US20140080175A1 (en) | 2012-03-29 | 2014-03-20 | Endocyte, Inc. | Processes for preparing tubulysin derivatives and conjugates thereof |
| WO2013173393A1 (en) | 2012-05-15 | 2013-11-21 | Concortis Biosystems, Corp | Drug-conjugates, conjugation methods, and uses thereof |
| AU2012385228B2 (en) * | 2012-07-12 | 2016-10-06 | Hangzhou Dac Biotech Co., Ltd | Conjugates of cell binding molecules with cytotoxic agents |
| US11873281B2 (en) | 2012-07-12 | 2024-01-16 | Hangzhou Dac Biotech Co., Ltd. | Conjugates of cell binding molecules with cytotoxic agents |
| MX2015004757A (es) | 2012-10-16 | 2015-07-17 | Endocyte Inc | Conjugados de suministro de farmacos que contienen aminoacidos no naturales y metodo para usarlos. |
| BR112015019432A2 (pt) | 2013-02-14 | 2017-08-22 | Bristol Myers Squibb Co | Compostos de tubulisina, métodos de produção e uso |
| MY183572A (en) | 2013-03-15 | 2021-02-26 | Regeneron Pharma | Biologically active molecules, conjugates thereof, and therapeutic uses |
| WO2014197866A1 (en) | 2013-06-06 | 2014-12-11 | Igenica Biotherapeutics, Inc. | Modified antibodies and related compounds, compositions, and methods of use |
| WO2014197871A2 (en) * | 2013-06-06 | 2014-12-11 | Igenica Biotherapeutics, Inc. | Antibody-drug conjugates, compositions and methods of use |
| FR3008408B1 (fr) * | 2013-07-11 | 2018-03-09 | Mc Saf | Nouveaux conjugues anticorps-medicament et leur utilisation en therapie |
| EA038192B1 (ru) | 2013-08-26 | 2021-07-21 | Регенерон Фармасьютикалз, Инк. | Фармацевтические композиции, содержащие диастереомеры макролида, способы их синтезирования и терапевтическое применение |
| US20150071923A1 (en) | 2013-09-12 | 2015-03-12 | Ge Wei | Modified anti-epidermal growth factor receptor antibodies and methods of use thereof |
| US10836821B2 (en) | 2013-10-15 | 2020-11-17 | Sorrento Therapeutics, Inc. | Drug-conjugates with a targeting molecule and two different drugs |
| PL3086815T3 (pl) | 2013-12-27 | 2022-06-13 | Zymeworks Inc. | Układy łącznikowe dla koniugatów leków zawierające ugrupowanie sulfonamidowe |
| CN106132959B (zh) * | 2014-01-28 | 2020-04-17 | 管道制药有限责任公司 | 用于缀合的细胞毒性微管溶素化合物 |
| EP3100731A4 (en) * | 2014-01-29 | 2017-12-20 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Ligand-cytotoxicity drug conjugate, preparation method therefor, and uses thereof |
| GB201402009D0 (en) | 2014-02-06 | 2014-03-26 | Oncomatryx Biopharma S L | Antibody-drug conjugates and immunotoxins |
| GB201402006D0 (en) | 2014-02-06 | 2014-03-26 | Oncomatryx Biopharma S L | Antibody-drug conjugates and immunotoxins |
| WO2015123687A1 (en) | 2014-02-14 | 2015-08-20 | Centrose, Llc | Extracellular targeted drug conjugates |
| LT3126388T (lt) | 2014-03-11 | 2019-08-26 | Regeneron Pharmaceuticals, Inc. | Antikūnai prieš egfrviii ir jų panaudojimo būdai |
| CA2945318A1 (en) * | 2014-04-11 | 2015-10-15 | Medimmune, Llc | Tubulysin derivatives |
| CA2950155C (en) | 2014-06-02 | 2021-11-23 | Regeneron Pharmaceuticals, Inc. | Biologically active molecule conjugates, reagents and methods of manufacture, and therapeutic uses |
| CA2950840C (en) | 2014-06-03 | 2023-09-26 | Xbiotech Inc. | Compositions and methods for treating and preventing staphylococcus aureus infections |
| CA2959424C (en) | 2014-09-11 | 2023-10-31 | Seattle Genetics, Inc. | Targeted delivery of tertiary amine-containing drug substances |
| CA3203273A1 (en) | 2014-10-14 | 2016-04-21 | Halozyme, Inc. | Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same |
| EP3209334A2 (en) * | 2014-10-20 | 2017-08-30 | Igenica Biotherapeutics, Inc. | Novel antibody-drug conjugates and related compounds, compositions, and methods of use |
| SG11201703446RA (en) | 2014-10-31 | 2017-05-30 | Abbvie Biotherapeutics Inc | Anti-cs1 antibodies and antibody drug conjugates |
| EP3215538A4 (en) * | 2014-11-07 | 2018-07-04 | Igenica Biotherapeutics, Inc. | Anti-cd39 antibodies and uses thereof |
| US10077287B2 (en) | 2014-11-10 | 2018-09-18 | Bristol-Myers Squibb Company | Tubulysin analogs and methods of making and use |
| BR112017012342A2 (pt) | 2014-12-09 | 2018-02-27 | Abbvie Inc | compostos inibitórios de bcl-xl e conjugados de anticorpo-fármaco incluindo os mesmos |
| US20160339117A1 (en) | 2014-12-09 | 2016-11-24 | Abbvie Inc. | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same |
| EP3229844B1 (en) | 2014-12-09 | 2020-03-04 | AbbVie Inc. | Antibody drug conjugates with cell permeable bcl-xl inhibitors |
| WO2016115201A1 (en) | 2015-01-14 | 2016-07-21 | Bristol-Myers Squibb Company | Heteroarylene-bridged benzodiazepine dimers, conjugates thereof, and methods of making and using |
| ES2918425T3 (es) | 2015-01-28 | 2022-07-15 | Sorrento Therapeutics Inc | Conjugados de anticuerpo-fármaco |
| US10676773B2 (en) * | 2015-03-10 | 2020-06-09 | Bristol-Myers Squibb Company | Antibodies conjugatable by transglutaminase and conjugates made therefrom |
| KR102708103B1 (ko) | 2015-03-27 | 2024-09-20 | 리제너론 파아마슈티컬스, 인크. | 메이탄시노이드 유도체, 이의 컨주게이트, 및 사용 방법 |
| WO2016165762A1 (en) * | 2015-04-15 | 2016-10-20 | Ganymed Pharmaceuticals Ag | Drug conjugates comprising antibodies against claudin 18.2 |
| CN106267225B (zh) | 2015-05-29 | 2020-03-06 | 上海新理念生物医药科技有限公司 | 三马来酰亚胺型连接子及其应用 |
| CN106279352B (zh) | 2015-05-29 | 2020-05-22 | 上海新理念生物医药科技有限公司 | 海兔毒素10的衍生物及其应用 |
| IL296285A (en) | 2015-07-06 | 2022-11-01 | Regeneron Pharma | Multispecific antigen-binding molecules and uses thereof |
| JP6817288B2 (ja) * | 2015-08-10 | 2021-01-20 | ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ．Ｈａｎｇｚｈｏｕ Ｄａｃ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． | 新規な連結体及び生体分子と薬物との特異的共役におけるその使用 |
| JP7330515B2 (ja) * | 2015-08-10 | 2023-08-22 | ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ． | 新規な連結体及び生体分子と薬物との特異的共役におけるその使用 |
| CA2994853C (en) * | 2015-08-14 | 2023-06-27 | Rc Biotechnologies, Inc. | Covalent linkers in antibody-drug conjugates and methods of making and using the same |
| EP3347049B1 (en) * | 2015-09-08 | 2024-07-03 | Waters Technologies Corporation | Multidimensional chromatography method for analysis of antibody-drug conjugates |
| US10195209B2 (en) | 2015-11-30 | 2019-02-05 | Abbvie Inc. | Anti-huLRRC15 antibody drug conjugates and methods for their use |
| EP3383909B1 (en) | 2015-11-30 | 2020-06-17 | AbbVie Inc. | Anti-human lrrc15 antibody drug conjugates and methods for their use |
| TWI814699B (zh) * | 2015-12-04 | 2023-09-11 | 美商思進公司 | 四級胺化妥布賴森(tubulysin)化合物之結合物 |
| US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
| RS62412B1 (sr) | 2015-12-09 | 2021-10-29 | Univ Wien Med | Jedinjenja platine funkcionalizovana sa monomaleimidom za terapiju raka |
| MA43416A (fr) | 2015-12-11 | 2018-10-17 | Regeneron Pharma | Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3 |
| AU2017211120C1 (en) | 2016-01-25 | 2021-10-07 | Regeneron Pharmaceuticals, Inc. | Maytansinoid derivatives, conjugates thereof, and methods of use |
| US20190365913A1 (en) * | 2016-02-04 | 2019-12-05 | Tarveda Therapeutics, Inc. | Stapled peptide conjugates and particles |
| WO2017161206A1 (en) | 2016-03-16 | 2017-09-21 | Halozyme, Inc. | Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use |
| MA45328A (fr) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Compositions acide nucléique-polypeptide et utilisations de celles-ci |
| US11352446B2 (en) | 2016-04-28 | 2022-06-07 | Regeneron Pharmaceuticals, Inc. | Methods of making multispecific antigen-binding molecules |
| SMT202000467T1 (it) | 2016-05-17 | 2020-11-10 | Abbvie Inc | Coniugati anticorpo-farmaco anti-cmet e metodi per il loro uso |
| JP2019524649A (ja) | 2016-06-08 | 2019-09-05 | アッヴィ・インコーポレイテッド | 抗ｃｄ９８抗体及び抗体薬物コンジュゲート |
| BR112018075644A2 (pt) | 2016-06-08 | 2019-04-09 | Abbvie Inc. | anticorpos anti-cd98 e conjugados de anticorpo e fármaco |
| EP3468616A1 (en) | 2016-06-08 | 2019-04-17 | AbbVie Inc. | Anti-egfr antibody drug conjugates |
| CN109563167A (zh) | 2016-06-08 | 2019-04-02 | 艾伯维公司 | 抗b7-h3抗体和抗体药物偶联物 |
| EP4364754A3 (en) | 2016-06-08 | 2025-02-12 | AbbVie Inc. | Anti-b7-h3 antibodies and antibody drug conjugates |
| EP3468615A1 (en) | 2016-06-08 | 2019-04-17 | AbbVie Inc. | Anti-egfr antibody drug conjugates |
| BR112018075649A2 (pt) | 2016-06-08 | 2019-04-09 | Abbvie Inc. | anticorpos anti-b7-h3 e conjugados de fármaco de anticorpo |
| MX2018015274A (es) | 2016-06-08 | 2019-10-07 | Abbvie Inc | Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco. |
| PH12018502602B1 (en) | 2016-06-08 | 2023-08-16 | Abbvie Inc | Anti-egfr antibody drug conjugates |
| EP3478324A1 (en) | 2016-07-01 | 2019-05-08 | GlaxoSmithKline Intellectual Property (No.2) Limited | Antibody-drug conjugates and therapeutic methods using the same |
| WO2018031690A1 (en) | 2016-08-09 | 2018-02-15 | Seattle Genetics, Inc. | Drug conjugates with self-stabilizing linkers having improved physiochemical properties |
| US10941208B2 (en) | 2016-09-23 | 2021-03-09 | Regeneron Pharmaceuticals, Inc. | Anti-MUC16 antibodies |
| MX2019003325A (es) | 2016-09-23 | 2019-08-05 | Regeneron Pharma | Anticuerpos anti-steap2, conjugados anticuerpo-farmaco, y moleculas de fijacion al antigeno biespecificas que se fijan a steap2 y cd3, y usos de estos. |
| WO2018089373A2 (en) | 2016-11-08 | 2018-05-17 | Regeneron Pharmaceuticals, Inc. | Steroids and protein-conjugates thereof |
| TWI782930B (zh) | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法 |
| CN109810039B (zh) * | 2017-11-22 | 2021-11-12 | 迈威(上海)生物科技股份有限公司 | 一种用于抗体-药物偶联的双取代马来酰胺类连接子及其制备方法和用途 |
| US10864279B2 (en) | 2016-12-16 | 2020-12-15 | Industrial Technology Research Institute | Linker-drug and antibody-drug conjugate (ADC) employing the same |
| MX2019011957A (es) * | 2017-04-06 | 2019-11-07 | Hangzhou Dac Biotech Co Ltd | Conjugacion de un farmaco citotoxico con enlace bis. |
| CA3063871A1 (en) | 2017-05-18 | 2018-11-22 | Regeneron Pharmaceuticals, Inc. | Cyclodextrin protein drug conjugates |
| JP7348844B2 (ja) | 2017-06-07 | 2023-09-21 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 内部移行酵素のための組成物および方法 |
| CN107652219B (zh) | 2017-08-14 | 2021-06-08 | 上海新理念生物医药科技有限公司 | 四马来酰亚胺型连接子及其应用 |
| SG11202001907QA (en) * | 2017-09-20 | 2020-04-29 | Ph Pharma Co Ltd | Thailanstatin analogs |
| IL274427B2 (en) | 2017-11-07 | 2024-11-01 | Regeneron Pharma | Hydrophilic linkers for antibody drug conjugates |
| CA3086926A1 (en) | 2018-01-08 | 2019-07-11 | Regeneron Pharmaceuticals, Inc. | Steroids and antibody-conjugates thereof |
| JP7328990B2 (ja) | 2018-04-30 | 2023-08-17 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｈｅｒ２及び／またはａｐｌｐ２に結合する抗体及び二重特異性抗原結合分子、ならびにそれらのコンジュゲート及び使用 |
| CA3098453A1 (en) | 2018-05-09 | 2019-11-14 | Regeneron Pharmaceuticals, Inc. | Anti-msr1 antibodies and methods of use thereof |
| EP3793591A1 (en) | 2018-05-17 | 2021-03-24 | Regeneron Pharmaceuticals, Inc. | Anti-cd63 antibodies, conjugates, and uses thereof |
| US11492409B2 (en) | 2018-06-01 | 2022-11-08 | Novartis Ag | Binding molecules against BCMA and uses thereof |
| CN109602915A (zh) * | 2018-07-03 | 2019-04-12 | 烟台迈百瑞国际生物医药有限公司 | 抗体-t2毒素缀合物及其用途 |
| IL321690A (en) | 2018-07-26 | 2025-08-01 | Curevac Netherlands B V | Cancer vaccines for uterine cancer |
| WO2020022900A1 (en) | 2018-07-26 | 2020-01-30 | Frame Pharmaceuticals B.V. | Cancer vaccines for kidney cancer |
| IL280111B1 (en) | 2018-07-26 | 2025-07-01 | Curevac Netherlands B V | arid1a, cdkn2a, kmt2b, kmt2d, tp53 and pten vaccines against cancer |
| EP3827263A1 (en) | 2018-07-26 | 2021-06-02 | Frame Pharmaceuticals B.V. | Cancer vaccines for colorectal cancer |
| CA3106564A1 (en) | 2018-07-26 | 2020-01-30 | Frame Pharmaceuticals B.V. | Cancer vaccines for breast cancer |
| JP2022512057A (ja) * | 2018-12-17 | 2022-02-02 | 栄昌生物制薬（烟台）股▲分▼有限公司 | 抗体薬物複合体のためのリンカーおよびその使用 |
| IL319265A (en) | 2018-12-21 | 2025-04-01 | Avidity Biosciences Inc | Anti-transferrin receptor antibodies and their uses |
| EP3897841A1 (en) | 2018-12-21 | 2021-10-27 | Regeneron Pharmaceuticals, Inc. | Rifamycin analogs and antibody-drug conjugates thereof |
| SG11202108525VA (en) | 2019-02-21 | 2021-09-29 | Regeneron Pharma | Methods of treating ocular cancer using anti-met antibodies and bispecific antigen binding molecules that bind met |
| JP7576779B2 (ja) | 2019-07-19 | 2024-11-01 | イミューンセンサー セラピューティクス、インコーポレイテッド | 抗体－ｓｔｉｎｇアゴニスト複合体および免疫療法におけるそれらの使用 |
| WO2021022678A1 (zh) | 2019-08-07 | 2021-02-11 | 烟台迈百瑞国际生物医药股份有限公司 | 一种抗体药物偶联物及其应用 |
| AU2020349462A1 (en) | 2019-09-16 | 2022-03-03 | Regeneron Pharmaceuticals, Inc. | Radiolabeled MET binding proteins for immuno-PET imaging |
| US11814428B2 (en) | 2019-09-19 | 2023-11-14 | Regeneron Pharmaceuticals, Inc. | Anti-PTCRA antibody-drug conjugates and uses thereof |
| IL295312A (en) | 2020-02-28 | 2022-10-01 | Regeneron Pharma | Bispecific antigen binding molecules that bind her2, and methods of use thereof |
| US20230126689A1 (en) | 2020-03-06 | 2023-04-27 | Go Therapeutics, Inc. | Anti-glyco-cd44 antibodies and their uses |
| CA3172111A1 (en) | 2020-03-19 | 2021-09-23 | Barbora MALECOVA | Compositions and methods of treating facioscapulohumeral muscular dystrophy |
| MX2022011880A (es) | 2020-03-27 | 2022-10-20 | Avidity Biosciences Inc | Composiciones y metodos para tratar distrofia muscular. |
| JP2023521885A (ja) | 2020-04-16 | 2023-05-25 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ディールス－アルダーコンジュゲーション方法 |
| MX2023000544A (es) | 2020-07-13 | 2023-02-13 | Regeneron Pharma | Conjugados de proteina-farmaco que comprenden analogos de camptotecina y metodos de uso de los mismos. |
| WO2022056494A1 (en) | 2020-09-14 | 2022-03-17 | Regeneron Pharmaceuticals, Inc. | Antibody-drug conjugates comprising glp1 peptidomimetics and uses thereof |
| JP2023547323A (ja) | 2020-10-22 | 2023-11-10 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗ｆｇｆｒ２抗体及びその使用方法 |
| UY39610A (es) | 2021-01-20 | 2022-08-31 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
| JP2024512324A (ja) | 2021-03-05 | 2024-03-19 | ジーオー セラピューティクス，インコーポレイテッド | 抗グリコｃｄ４４抗体およびその使用 |
| US20250101126A1 (en) | 2021-08-05 | 2025-03-27 | Go Therapeutics, Inc. | Anti-glyco-muc4 antibodies and their uses |
| US11807685B2 (en) * | 2021-08-05 | 2023-11-07 | The Uab Research Foundation | Anti-CD47 antibody and uses thereof |
| JP2024536722A (ja) | 2021-09-03 | 2024-10-08 | ジーオー セラピューティクス，インコーポレイテッド | 抗グリコｃｍｅｔ抗体およびその使用 |
| KR20240101546A (ko) | 2021-09-03 | 2024-07-02 | 고 테라퓨틱스, 인크. | 항-글리코-lamp1 항체 및 그의 용도 |
| WO2023043953A1 (en) | 2021-09-16 | 2023-03-23 | Avidity Biosciences, Inc. | Compositions and methods of treating facioscapulohumeral muscular dystrophy |
| US20230287138A1 (en) | 2022-01-12 | 2023-09-14 | Regneron Pharmaceuticals, Inc. | Protein-drug conjugates comprising camptothecin analogs and methods of use thereof |
| WO2023173132A1 (en) | 2022-03-11 | 2023-09-14 | Regeneron Pharmaceuticals, Inc. | Anti-glp1r antibody-drug conjugates comprising glp1 peptidomimetics and uses thereof |
| AU2023310999A1 (en) | 2022-07-21 | 2025-01-23 | Firefly Bio, Inc. | Glucocorticoid receptor agonists and conjugates thereof |
| CN115814111B (zh) * | 2022-12-05 | 2025-03-28 | 复旦大学附属中山医院 | 一种近红外荧光adc免疫制剂及其制备方法与应用 |
| AU2023407365A1 (en) | 2022-12-21 | 2025-07-31 | Regeneron Pharmaceuticals, Inc. | Prodrugs of topoisomerase i inhibitor for adc conjugations and methods of use thereof |
| WO2024229105A1 (en) | 2023-05-02 | 2024-11-07 | Regeneron Pharmaceuticals, Inc. | Anti-human m-cadherin (cdh15) antibodies, conjugates, and uses thereof for delivery of genetic payloads to muscle cells |
| WO2025014533A1 (en) | 2023-07-10 | 2025-01-16 | Regeneron Pharmaceuticals, Inc. | Anti-human cacng1 antibody-drug conjugates and uses thereof |
| WO2025096921A1 (en) | 2023-11-03 | 2025-05-08 | Regeneron Pharmaceuticals, Inc. | Peptide acids as a glp1r agonist and antibody-drug conjugates thereof |
| WO2025114426A1 (en) | 2023-11-28 | 2025-06-05 | Universite De Strasbourg | Preparation of protein conjugates via one-pot multicomponent reaction |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100475492B1 (ko) * | 1995-01-26 | 2005-03-14 | 바이오겐 아이덱 엠에이 인코포레이티드 | 항종양제로서의 림프독소-α/β 복합체 및항-림프독소-β수용체 항체 |
| CA2802205C (en) * | 2002-07-31 | 2016-01-19 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
| DE10254439A1 (de) * | 2002-11-21 | 2004-06-03 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | Tubulysine, Herstellungsverfahren und Tubulysin-Mittel |
| EP3858387A1 (en) * | 2003-11-06 | 2021-08-04 | Seagen Inc. | Monomethylvaline compounds capable of conjugation to ligands |
| US7740861B2 (en) * | 2004-06-16 | 2010-06-22 | University Of Massachusetts | Drug delivery product and methods |
| WO2006034488A2 (en) * | 2004-09-23 | 2006-03-30 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
| EP1996234A2 (en) * | 2005-09-20 | 2008-12-03 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Nanoparticles for targeted delivery of active agents |
| KR20100093578A (ko) * | 2007-11-30 | 2010-08-25 | 브리스톨-마이어스 스큅 컴퍼니 | 항-비7에이취4 단일클론 항체-약물 접합체 및 그 사용 방법 |
| BRPI0914789A2 (pt) * | 2008-06-16 | 2015-10-20 | Immunogen Inc | efeitos sinérgicos |
| SG192517A1 (en) * | 2008-07-15 | 2013-08-30 | Genentech Inc | Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds |
| JP5954789B2 (ja) * | 2009-08-10 | 2016-07-20 | ユーシーエル ビジネス パブリック リミテッド カンパニー | 機能的分子の可逆的共有結合 |
| JP2015510877A (ja) * | 2012-03-09 | 2015-04-13 | ユーシーエル ビジネス パブリック リミテッド カンパニー | 抗体の化学修飾 |
-
2012
- 2012-12-04 CN CN201280067454.XA patent/CN104244718A/zh active Pending
- 2012-12-04 CA CA2857398A patent/CA2857398A1/en not_active Abandoned
- 2012-12-04 SG SG11201402686UA patent/SG11201402686UA/en unknown
- 2012-12-04 EP EP12855849.1A patent/EP2793585A4/en not_active Withdrawn
- 2012-12-04 BR BR112014013526A patent/BR112014013526A2/pt not_active Application Discontinuation
- 2012-12-04 HK HK15104134.2A patent/HK1203309A1/xx unknown
- 2012-12-04 KR KR1020147018663A patent/KR20140139480A/ko not_active Withdrawn
- 2012-12-04 MX MX2014006739A patent/MX2014006739A/es unknown
- 2012-12-04 JP JP2014546004A patent/JP2015500287A/ja active Pending
- 2012-12-04 RU RU2014124984A patent/RU2014124984A/ru not_active Application Discontinuation
- 2012-12-04 US US13/705,074 patent/US20130224228A1/en not_active Abandoned
- 2012-12-04 AU AU2012348017A patent/AU2012348017A1/en not_active Abandoned
- 2012-12-04 WO PCT/US2012/067803 patent/WO2013085925A1/en active Application Filing
- 2012-12-04 IN IN4961CHN2014 patent/IN2014CN04961A/en unknown
-
2014
- 2014-05-29 ZA ZA2014/03946A patent/ZA201403946B/en unknown
- 2014-05-30 PH PH12014501229A patent/PH12014501229A1/en unknown
- 2014-06-02 IL IL232936A patent/IL232936A0/en unknown
-
2015
- 2015-08-24 US US14/834,078 patent/US20160303247A1/en not_active Abandoned
-
2019
- 2019-12-27 US US16/728,045 patent/US20200392108A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20160303247A1 (en) | 2016-10-20 |
| EP2793585A4 (en) | 2015-12-09 |
| SG11201402686UA (en) | 2014-06-27 |
| MX2014006739A (es) | 2015-06-05 |
| HK1203309A1 (zh) | 2015-10-30 |
| AU2012348017A1 (en) | 2014-07-03 |
| WO2013085925A1 (en) | 2013-06-13 |
| CA2857398A1 (en) | 2013-06-13 |
| PH12014501229A1 (en) | 2014-09-08 |
| BR112014013526A8 (pt) | 2017-06-13 |
| US20130224228A1 (en) | 2013-08-29 |
| EP2793585A1 (en) | 2014-10-29 |
| IL232936A0 (en) | 2014-07-31 |
| KR20140139480A (ko) | 2014-12-05 |
| CN104244718A (zh) | 2014-12-24 |
| IN2014CN04961A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2015-09-18 |
| ZA201403946B (en) | 2015-09-30 |
| BR112014013526A2 (pt) | 2017-06-13 |
| JP2015500287A (ja) | 2015-01-05 |
| US20200392108A1 (en) | 2020-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014124984A (ru) | Конъюгаты антитело-лекарственное средство и родственные соединения, композиции и способы | |
| JP7254861B2 (ja) | エリブリンをベースとする抗体－薬物コンジュゲート及び使用方法 | |
| JP2019532056A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| RU2487877C2 (ru) | Высокоэффективные конъюгаты и гидрофильные сшивающие агенты (линкеры) | |
| JP2019536740A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| JP2023089195A (ja) | グリピカン３抗体およびそのコンジュゲート | |
| RU2014146951A (ru) | Конъюгаты типа лиганд dr5-лекарственное средство | |
| WO2021207701A1 (en) | Charge variant linkers | |
| RU2016133846A (ru) | Конъюгат лиганд - цитотоксическое лекарственное средство, способ его получения и его применения | |
| RU2015119561A (ru) | Новые конъюгаты лекарственное вещество-белок | |
| JP2016523810A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| RU2015119557A (ru) | Конъюгаты лекарственное вещество-белок | |
| MX2020011554A (es) | Composiciones y metodos relacionados con conjugados de farmacos de anticuerpo anti grupo de diferenciacion 19 (cd19). | |
| EA035374B1 (ru) | Антитела против cd48 и их конъюгаты | |
| EA200600275A1 (ru) | Цитотоксический конъюгат, специфичный по отношению к са6 антигену, и способы его применения | |
| RU2016139340A (ru) | Коньюгаты "антитело - лекарственное средство" с высокой лекарственной нагрузкой | |
| JP7695260B2 (ja) | Ｈｅｒ２に結合する二重特異性抗原結合分子およびその使用方法 | |
| PE20120899A1 (es) | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b | |
| RU2016129894A (ru) | Ковалентно связанные конъюгаты хеликар-антитело против хеликара и их применения | |
| EA201490957A1 (ru) | Лечение гематологических злокачественных заболеваний с помощью анти-cxcr4 антитела | |
| RU2009110102A (ru) | Лечение опухолей с помощью антитела к vegf | |
| MY153893A (en) | Antibodies against human il17 and uses thereof | |
| RU2014128467A (ru) | Новые коньюгаты связывающее соединение-активное соединение (adc) и их применение | |
| IL278574B2 (en) | Glycan-interacting compounds and methods of use | |
| RU2013151599A (ru) | Новые конъюгаты связывающее соединение-активное соединение (adc) и их применение |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20170721 |